NEW YORK (GenomeWeb) – Labsco said today that it has inked an exclusive partnership with BioFire Diagnostics, a BioMérieux subsidiary, to sell BioFire's FilmArray system in certain market segments in the US.
Under the agreement, Labsco will be an exclusive sales agent partner for the FilmArray system in small hospital laboratories and physician office laboratories in the 48 contiguous states. Labsco will be responsible for selling, account management, local marketing, and contract presentation and execution for transition contracts and new contracts.
FilmArray is a CE-marked and US Food and Drug Administration-cleared multiplex PCR system that identifies the most common disease-causing organisms responsible for a syndrome. FilmArray’s menu currently comprises three panels — respiratory, blood culture identification, and gastrointestinal — all of which are CE-marked and FDA-cleared. Additionally, BioFire has submitted a de novo application to the FDA for its meningitis-encephalitis panel.
"We chose Labsco due to their lab focus, clinical sales expertise, customer intimacy, and proven molecular track record in key market segments where BioFire has the potential to develop," BioFire Diagnostics CEO Randy Rasmussen said in a statement. "We are confident this relationship will help drive further adoption of the FilmArray's syndromic approach for the diagnosis of infectious diseases."